Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 180

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure

van der Putten, Karien, Braam, Branko, Jie, Kim E, Gaillard, Carlo AJM·2008·Nature Clinical Practice Nephrology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncpneph0655

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 97

  1. Bongartz LG et al. (2005) The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 26: 11–17 · DOI · Paper page
  2. Jie KE et al. (2006) Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol 291: F932–F944 · DOI
  3. Fehr T et al. (2004) Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. Kidney Int 66: 1206–1211 · DOI
  4. Jacobs C et al. (2003) Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol Dial Transplant 20 (Suppl 3): Siii3–Siii24
  5. Eckhardt KU (2000) Pathophysiology of renal anemia. Clin Nephrol 53 (Suppl 1): S2–S8
  6. Drueke TB and Eckardt KU (2002) Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. Nephrol Dial Transplant 17 (Suppl 5): S28–S31 · doi:10.1093/ndt/17.suppl_5.28
  7. de Silva R et al. (2006) Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am J Cardiol 98: 391–398 · DOI
  8. Macdougall IC (1999) The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrol Dial Transplant 14: 1836–1841 · DOI
  9. Saudan P et al. (2006) ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance. J Nephrol 19: 91–96
  10. Opasich C et al. (2005) Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 26: 2232–2237 · DOI · Paper page
  11. Anand IS (2005) Pathogenesis of anemia in cardiorenal disease. Rev Cardiovasc Med 6 (Suppl 3): S13–S21
  12. Mrug M et al. (1997) Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 100: 2310–2314 · DOI · Paper page
  13. Azizi M et al. (1996) Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 97: 839–844 · DOI · Paper page
  14. van der Meer P et al. (2005) Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 112: 1743–1747 · DOI
  15. Albitar S et al. (1998) High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 13: 1206–1210 · doi:10.1093/ndt/13.5.1206
  16. Erturk S et al. (1999) The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients. Nephrol Dial Transplant 14: 1912–1916 · doi:10.1093/ndt/14.8.1912
  17. Ishani A et al. (2005) Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 45: 391–399 · DOI · Paper page
  18. Androne AS et al. (2003) Hemodilution is common in patients with advanced heart failure. Circulation 107: 226–229 · DOI · Paper page
  19. Silverberg DS et al. (2002) The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization. Clin Nephrol 58 (Suppl 1): S37–S45
  20. Levin A et al. (1999) Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 34: 125–134 · DOI · Paper page
  21. Foley RN et al. (1996) The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28: 53–61 · DOI · Paper page
  22. Ma JZ et al. (1999) Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10: 610–619 · DOI · Paper page
  23. Parfrey PS et al. (2005) Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16: 2180–2189 · DOI · Paper page
  24. Collins AJ et al. (2001) Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 12: 2465–2473 · DOI · Paper page
  25. Xue JL et al. (2002) Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis 40: 1153–1161 · DOI
  26. Locatelli F et al. (2004) Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19: 121–132 · DOI · Paper page
  27. Regidor DL et al. (2006) Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17: 1181–1191 · DOI · Paper page
  28. Jones M et al. (2004) Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int 65: 757–767 · DOI · Paper page
  29. Goldberg N et al. (1992) Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin. Am Heart J 124: 424–427 · DOI
  30. Frank H et al. (2004) Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients. Kidney Int 66: 832–840 · DOI
  31. Drueke TB et al. for the CREATE Investigators (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071–2084 · DOI · Paper page
  32. Locatelli F et al. (2004) Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19 (Suppl 2): Sii1–Sii47
  33. Anand I et al. (2004) Anemia and its relationship to clinical outcome in heart failure. Circulation 110: 149–154 · DOI · Paper page
  34. Go AS et al. (2006) Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 113: 2713–2723 · DOI · Paper page
  35. Mancini DM et al. (2003) Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107: 294–299 · DOI · Paper page
  36. Silverberg DS et al. (2001) The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37: 1775–1780 · DOI · Paper page
  37. Ponikowski P et al. (2007) Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 49: 753–762 · DOI · Paper page
  38. Palazzuoli A et al. (2006) Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 152: 1096 e9–e15 · DOI · Paper page
  39. Ghali J et al. (2006) Randomized, double-blind, placebo-controlled trial to assess the impact of darbepoetin alfa treatment on exercise tolerance in anemic patients with symptomatic heart failure: results from STAMINA-HeFT (abstract #549). European Society of Cardiology Heart Failure Congress: 2006 17–20 June 2006, Helsinki, Finland · doi:10.1016/s1567-4215(06)80346-2
  40. Fisher JW et al. (1996) Erythropoietin production by interstitial cells of hypoxic monkey kidneys. Br J Haematol 95: 27–32 · doi:10.1046/j.1365-2141.1996.d01-1864.x
  41. Warnecke C et al. (2004) Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J 18: 1462–1464 · DOI · Paper page
  42. Scortegagna M et al. (2005) HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood 105: 3133–3140 · DOI · Paper page
  43. Imagawa S et al. (1997) Negative regulation of the erythropoietin gene expression by the GATA transcription factors. Blood 89: 1430–1439 · DOI
  44. La Ferla K et al. (2002) Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-kappaB. FASEB J 16: 1811–1813 · DOI
  45. Dumitriu B et al. (2006) Sox6 cell-autonomously stimulates erythroid cell survival, proliferation, and terminal maturation and is thereby an important enhancer of definitive erythropoiesis during mouse development. Blood 108: 1198–1207 · DOI
  46. Fisher JW (2003) Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 228: 1–14 · DOI · Paper page
  47. Wickrema A et al. (1992) Differentiation and erythropoietin receptor gene expression in human erythroid progenitor cells. Blood 80: 1940–1949 · DOI
  48. Anagnostou A et al. (1994) Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 91: 3974–3978 · DOI · Paper page
  49. Chong ZZ et al. (2002) Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J Cereb Blood Flow Metab 22: 503–514 · DOI · Paper page
  50. Henry DH et al. (2004) Epoetin alfa: clinical evolution of a pleiotropic cytokine. Arch Intern Med 164: 262–276 · DOI
  51. Bahlmann FH et al. (2004) Erythropoietin regulates endothelial progenitor cells. Blood 103: 921–926 · DOI · Paper page
  52. Bahlmann FH et al. (2003) Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 64: 1648–1652 · DOI · Paper page
  53. George J et al. (2005) Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc Res 68: 299–306 · DOI
  54. Beleslin-Cokic BB et al. (2004) Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 104: 2073–2080 · DOI · Paper page
  55. Parsa CJ et al. (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112: 999–1007 · DOI · Paper page
  56. Vesey DA et al. (2004) Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 19: 348–355 · DOI · Paper page
  57. Caro J et al. (1979) Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med 93: 449–458
  58. Mason-Garcia M et al. (1990) Development of a new radioimmunoassay for erythropoietin using recombinant erythropoietin. Kidney Int 38: 969–975 · doi:10.1038/ki.1990.299
  59. Macdougall IC (1995) Poor response to erythropoietin: practical guidelines on investigation and management. Nephrol Dial Transplant 10: 607–614 · doi:10.1093/ndt/10.supp2.85
  60. Volpe M et al. (1994) Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol 74: 468–473 · DOI
  61. Jensen JD et al. (1993) Elevated level of erythropoietin in congestive heart failure relationship to renal perfusion and plasma renin. J Intern Med 233: 125–130 · doi:10.1111/j.1365-2796.1993.tb00664.x
  62. George J et al. (2005) Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. Arch Intern Med 165: 1304–1309 · DOI
  63. van der Meer P et al. (2004) Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 44: 63–67 · DOI · Paper page
  64. Stenvinkel P (2001) Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif 19: 53–61 · DOI · Paper page
  65. Bergstrom J et al. (2000) What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients? Semin Dial 13: 163–175 · DOI
  66. Deswal A et al. (2001) Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103: 2055–2059 · DOI · Paper page
  67. Dutka DP et al. (1993) Tumour necrosis factor alpha in severe congestive cardiac failure. Br Heart J 70: 141–143 · DOI · Paper page
  68. Macdougall IC and Cooper AC (2002) Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 17 (Suppl 11): S39–S43 · DOI · Paper page
  69. Means RT Jr (2003) Recent developments in the anemia of chronic disease. Curr Hematol Rep 2: 116–121 · DOI
  70. Taniguchi S et al. (1997) Interferon gamma downregulates stem cell factor and erythropoietin receptors but not insulin-like growth factor-I receptors in human erythroid colony-forming cells. Blood 90: 2244–2252 · DOI · Paper page
  71. Mena NP et al. (2006) Regulation of transepithelial transport of iron by hepcidin. Biol Res 39: 191–193 · DOI
  72. Dallalio G et al. (2006) Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood 107: 2702–2704 · DOI
  73. Malyszko J et al. (2005) Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients? Am J Nephrol 25: 586–590 · DOI
  74. Eleftheriadis T et al. (2006) Does hepcidin affect erythropoiesis in hemodialysis patients? Acta Haematol 116: 238–244 · DOI
  75. Philo JS et al. (1996) Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction. Biochemistry 35: 1681–1691 · DOI · Paper page
  76. Constantinescu SN et al. (2001) Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci USA 98: 4379–4384 · DOI · Paper page
  77. Rossert J and Eckardt KU (2005) Erythropoietin receptors: their role beyond erythropoiesis. Nephrol Dial Transplant 20: 1025–1028 · DOI
  78. Naranda T et al. (1999) Activation of erythropoietin receptor in the absence of hormone by a peptide that binds to a domain different from the hormone binding site. Proc Natl Acad Sci USA 96: 7569–7574 · DOI
  79. Wrighton NC et al. (1996) Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273: 458–464 · DOI · Paper page
  80. Livnah O et al. (1996) Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 273: 464–471 · DOI · Paper page
  81. Sasaki A et al. (2000) CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem 275: 29338–29347 · DOI · Paper page
  82. Beckman DL et al. (1999) Activation of the erythropoietin receptor is not required for internalization of bound erythropoietin. Blood 94: 2667–2675 · doi:10.1182/blood.v94.8.2667.420k27_2667_2675
  83. Sorkin A and Waters CM (1993) Endocytosis of growth factor receptors. Bioessays 15: 375–382 · DOI · Paper page
  84. Walrafen P et al. (2005) Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood 105: 600–608 · DOI · Paper page
  85. Witthuhn BA et al. (1993) JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 74: 227–236 · DOI · Paper page
  86. Klingmuller U et al. (1995) Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80: 729–738 · DOI · Paper page
  87. Akagi S et al. (2004) The critical role of SRC homology domain 2-containing tyrosine phosphatase-1 in recombinant human erythropoietin hyporesponsive anemia in chronic hemodialysis patients. J Am Soc Nephrol 15: 3215–3224 · DOI
  88. Silva M et al. (1996) Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 88: 1576–1582 · DOI · Paper page
  89. Matsumoto A et al. (1997) CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 89: 3148–3154 · DOI · Paper page
  90. Peltola KJ et al. (2004) Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. Blood 103: 3744–3750 · DOI
  91. Miura Y et al. (1994) Activation of the mitogen-activated protein kinase pathway by the erythropoietin receptor. J Biol Chem 269: 29962–29969 · DOI · Paper page
  92. Carroll MP et al. (1991) Erythropoietin induces Raf-1 activation and Raf-1 is required for erythropoietin-mediated proliferation. J Biol Chem 266: 14964–14969 · DOI · Paper page
  93. Miura O et al. (1994) Erythropoietin-dependent association of phosphatidylinositol 3-kinase with tyrosine-phosphorylated erythropoietin receptor. J Biol Chem 269: 614–620 · DOI
  94. Kashii Y et al. (2000) A member of Forkhead family transcription factor, FKHRL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction. Blood 96: 941–949 · DOI · Paper page
  95. Rice L et al. (2001) Neocytolysis on descent from altitude: a newly recognized mechanism for the control of red cell mass. Ann Intern Med 134: 652–656 · DOI
  96. Trial J and Rice L (2004) Erythropoietin withdrawal leads to the destruction of young red cells at the endothelial-macrophage interface. Curr Pharm Des 10: 183–190 · doi:10.2174/1381612043453423
  97. Rice L et al. (1999) Neocytolysis contributes to the anemia of renal disease. Am J Kidney Dis 33: 59–62 · doi:10.1016/s0272-6386(99)70258-1

Cited by

See all 180

Metadata

Authors
van der Putten, K., Braam, B., Jie, K. E., & Gaillard, C. A.
Venue
Nature Clinical Practice Nephrology
Published
2008-01
Volume
4
Issue
1
Pages
47-57
ISSN
  • 1745-8323 (ISSN-L)
  • 1745-8331
OpenAlex
W2010494541
Cited by
180
References
10
FWCI
0.81
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.